BioLife Solutions (BLFS) Expected to Post Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is expected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect BioLife Solutions to announce earnings of $0.0271 per share and revenue of $27.7960 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The company had revenue of $27.50 million during the quarter, compared to the consensus estimate of $25.66 million. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Price Performance

BLFS opened at $32.52 on Wednesday. BioLife Solutions has a fifty-two week low of $17.86 and a fifty-two week high of $33.14. The firm has a market capitalization of $1.59 billion, a PE ratio of -406.45 and a beta of 1.93. The company’s 50-day moving average is $28.04 and its 200 day moving average is $23.86.

Analyst Ratings Changes

A number of brokerages have commented on BLFS. HC Wainwright lowered BioLife Solutions from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $32.00 to $31.00 in a report on Thursday, July 23rd. Maxim Group lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. Craig Hallum cut BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a research report on Wednesday, July 22nd. Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. Finally, Stephens reissued an “equal weight” rating and issued a $31.00 price target (down from $32.00) on shares of BioLife Solutions in a research report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, BioLife Solutions presently has a consensus rating of “Hold” and an average price target of $31.38.

Insider Buying and Selling at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $23.70, for a total value of $15,405,000.00. Following the transaction, the insider owned 4,757,165 shares in the company, valued at $112,744,810.50. The trade was a 12.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 1,200,000 shares of company stock valued at $28,125,000. 2.20% of the stock is owned by insiders.

Institutional Trading of BioLife Solutions

A number of hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC bought a new position in BioLife Solutions in the 4th quarter valued at $30,000. Kemnay Advisory Services Inc. purchased a new stake in shares of BioLife Solutions during the 4th quarter valued at $35,000. Quarry LP raised its stake in shares of BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares during the period. Strs Ohio bought a new stake in shares of BioLife Solutions during the 1st quarter worth $153,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of BioLife Solutions by 547.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock worth $154,000 after buying an additional 6,032 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.